{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:14:21Z","timestamp":1793146461173,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In human celiac disease (CeD) HLA-DQ2.5 presents gluten peptides to antigen-specific CD4<jats:sup>+<\/jats:sup> T cells, thereby instigating immune activation and enteropathy. Targeting HLA-DQ2.5 with neutralizing antibody for treating CeD may be plausible, yet using pan-HLA-DQ antibody risks affecting systemic immunity, while targeting selected gluten peptide:HLA-DQ2.5 complex (pHLA-DQ2.5) may be insufficient. Here we generate a TCR-like, neutralizing antibody (DONQ52) that broadly recognizes more than twenty-five distinct gluten pHLA-DQ2.5 through rabbit immunization with multi-epitope gluten pHLA-DQ2.5 and multidimensional optimization. Structural analyses show that the proline-rich and glutamine-rich motif of gluten epitopes critical for pathogenesis is flexibly recognized by multiple tyrosine residues present in the antibody paratope, implicating the mechanisms for the broad reactivity. In HLA-DQ2.5 transgenic mice, DONQ52 demonstrates favorable pharmacokinetics with high subcutaneous bioavailability, and blocks immunity to gluten while not affecting systemic immunity. Our results thus provide a rationale for clinical testing of DONQ52 in CeD.<\/jats:p>","DOI":"10.1038\/s41467-023-44083-4","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:02:05Z","timestamp":1703242925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6949-8105","authenticated-orcid":false,"given":"Yuu","family":"Okura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ikawa-Teranishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Mizoroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-6998","authenticated-orcid":false,"given":"Noriyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulkarnain","family":"Harfuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Miura-Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-4822","authenticated-orcid":false,"given":"Shunsuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-5494","authenticated-orcid":false,"given":"Hiroaki","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok Wan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hayasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-1291","authenticated-orcid":false,"given":"Tetsuya","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishiki","family":"Nagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Kuramochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-6123","authenticated-orcid":false,"given":"Takuya","family":"Torizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0476-1264","authenticated-orcid":false,"given":"Junichi","family":"Nezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-704X","authenticated-orcid":false,"given":"Ludvig M.","family":"Sollid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-8220","authenticated-orcid":false,"given":"Tomoyuki","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"44083_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nri3407","volume":"13","author":"LM Sollid","year":"2013","unstructured":"Sollid, L. M. & Jabri, B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat. Rev. Immunol. 13, 294\u2013302 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"44083_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0054-z","volume":"5","author":"K Lindfors","year":"2019","unstructured":"Lindfors, K. et al. Coeliac disease. Nat. Rev. Dis. Prim. 5, 3 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"44083_CR3","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/ajg.2014.355","volume":"109","author":"P Wacklin","year":"2014","unstructured":"Wacklin, P. et al. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am. J. Gastroenterol. 109, 1933\u20131941 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"44083_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/nu8070429","volume":"8","author":"P Laurikka","year":"2016","unstructured":"Laurikka, P. et al. Gastrointestinal symptoms in celiac disease patients on a long-term gluten-free diet. Nutrients 8, 429 (2016).","journal-title":"Nutrients"},{"key":"44083_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fped.2018.00350","volume":"6","author":"JA Tye-Din","year":"2018","unstructured":"Tye-Din, J. A., Galipeau, H. J. & Agardh, D. Celiac disease: a review of current concepts in pathogenesis, prevention, and novel therapies. Front. Pediatr. 6, 350 (2018).","journal-title":"Front. Pediatr."},{"key":"44083_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1128\/CMR.00048-08","volume":"22","author":"JM Blackwell","year":"2009","unstructured":"Blackwell, J. M., Jamieson, S. E. & Burgner, D. HLA and infectious diseases. Clin. Micobiol. Rev. 22, 370\u2013385 (2009).","journal-title":"Clin. Micobiol. Rev."},{"key":"44083_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fimmu.2013.00321","volume":"4","author":"S Tsai","year":"2013","unstructured":"Tsai, S. & Santamaria, P. MHC Class II Polymorphisms, Autoreactive\u2009T-Cells, and Autoimmunity. Front. Immunol. 4, 321 (2013).","journal-title":"Front. Immunol."},{"key":"44083_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-018-0354-x","volume":"11","author":"S Boegel","year":"2018","unstructured":"Boegel, S. et al. HLA and proteasome expression body map. BMC Med. Genom. 11, 36 (2018).","journal-title":"BMC Med. Genom."},{"key":"44083_CR9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1053\/j.gastro.2018.12.013","volume":"156","author":"LS H\u00f8ydahl","year":"2019","unstructured":"H\u00f8ydahl, L. S. et al. Plasma cells are the most abundant gluten peptide MHC-expressing cells in inflamed intestinal tissues from patients with celiac disease. Gastroenterology 156, 1428\u20131439.e10 (2019).","journal-title":"Gastroenterology"},{"key":"44083_CR10","doi-asserted-by":"publisher","first-page":"eabg4925","DOI":"10.1126\/sciimmunol.abg4925","volume":"6","author":"R Frick","year":"2021","unstructured":"Frick, R. et al. A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation. Sci. Immunol. 6, eabg4925 (2021).","journal-title":"Sci. Immunol."},{"key":"44083_CR11","doi-asserted-by":"publisher","first-page":"41ra51","DOI":"10.1126\/scitranslmed.3001012","volume":"2","author":"JA Tye-Din","year":"2010","unstructured":"Tye-Din, J. A. et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci. Transl. Med. 2, 41ra51 (2010).","journal-title":"Sci. Transl. Med."},{"key":"44083_CR12","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.4049\/jimmunol.0803181","volume":"182","author":"A Camarca","year":"2009","unstructured":"Camarca, A. et al. Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease. J. Immunol. 182, 4158\u20134166 (2009).","journal-title":"J. Immunol."},{"key":"44083_CR13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1053\/j.gastro.2015.07.013","volume":"149","author":"MY Hardy","year":"2015","unstructured":"Hardy, M. Y. et al. Consistency in polyclonal T-cell responses to gluten between children and adults with celiac disease. Gastroenterology 149, 1541\u20131552.e2 (2015).","journal-title":"Gastroenterology"},{"key":"44083_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00251-019-01141-w","volume":"72","author":"LM Sollid","year":"2020","unstructured":"Sollid, L. M., Qiao, S. W., Anderson, R. P., Gianfrani, C. & Koning, F. Update 2020: nomenclature and listing of celiac disease\u2013relevant gluten epitopes recognized by CD4+ T cells. Immunogenetics 72, 85\u201388 (2020).","journal-title":"Immunogenetics"},{"key":"44083_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1074\/jbc.RA118.005736","volume":"294","author":"S Dahal-Koirala","year":"2019","unstructured":"Dahal-Koirala, S. et al. Discriminative T-cell receptor recognition of highly homologous HLA-DQ2-bound gluten epitopes. J. Biol. Chem. 294, 941\u2013952 (2019).","journal-title":"J. Biol. Chem."},{"key":"44083_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/tpj.12851","volume":"82","author":"CV Ozuna","year":"2015","unstructured":"Ozuna, C. V. et al. Diversification of the celiac disease \u03b1-gliadin complex in wheat: a 33-mer peptide with six overlapping epitopes, evolved following polyploidization. Plant. J. 82, 794\u2013805 (2015).","journal-title":"Plant. J."},{"key":"44083_CR17","doi-asserted-by":"publisher","first-page":"e0209509","DOI":"10.1371\/journal.pone.0209509","volume":"13","author":"Z Sampei","year":"2018","unstructured":"Sampei, Z. et al. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS One. 13, e0209509 (2018).","journal-title":"PLoS One."},{"key":"44083_CR18","doi-asserted-by":"publisher","first-page":"2040350","DOI":"10.1080\/19420862.2022.2040350","volume":"14","author":"T Kuramochi","year":"2022","unstructured":"Kuramochi, T. et al. Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants. Mabs 14, 2040350 (2022).","journal-title":"Mabs"},{"key":"44083_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/19420862.2017.1314873","volume":"9","author":"A Maeda","year":"2017","unstructured":"Maeda, A. et al. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs 9, 844\u2013853 (2017).","journal-title":"MAbs"},{"key":"44083_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00251-014-0819-9","volume":"67","author":"E Bergseng","year":"2015","unstructured":"Bergseng, E. et al. Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires. Immunogenetics 67, 73\u201384 (2015).","journal-title":"Immunogenetics"},{"key":"44083_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1745-7580-5-2","volume":"5","author":"S Justesen","year":"2009","unstructured":"Justesen, S., Harndahl, M., Lamberth, K., Nielsen, L. B. & Buus, S. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immun. Res. 5, 2 (2009).","journal-title":"Immun. Res."},{"key":"44083_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/intimm\/6.3.453","volume":"6","author":"BH Johansen","year":"1994","unstructured":"Johansen, B. H. et al. Binding of peptides to HLA-DQ molecules: peptide binding properties of the disease-associated HLA-DQ(alpha 1*0501, beta 1*0201) molecule. Int. Immunol. 6, 453\u2013461 (1994).","journal-title":"Int. Immunol."},{"key":"44083_CR23","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.4049\/jimmunol.169.9.5098","volume":"169","author":"J Sidney","year":"2002","unstructured":"Sidney, J., del Gurecio, M. F., Southwood, S. & Sette, A. The HLA molecules DQA1*0501\/B1*0201 and DQA1*0301\/B1*0302 share an extensive overlap in peptide binding specificity. J. Immunol. 169, 5098\u20135108 (2002).","journal-title":"J. Immunol."},{"key":"44083_CR24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/apt.15477","volume":"50","author":"JA Tye-Din","year":"2019","unstructured":"Tye-Din, J. A. et al. Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Aliment. Pharmacol. Ther. 50, 901\u2013910 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"44083_CR25","doi-asserted-by":"publisher","first-page":"e1002404","DOI":"10.1371\/journal.pcbi.1002404","volume":"8","author":"CF Reboul","year":"2012","unstructured":"Reboul, C. F., Meyer, G. R., Porebski, B. T., Borg, N. A. & Buckle, A. M. Epitope flexibility and dynamic footprint revealed by molecular dynamics of a pMHC-TCR complex. PLOS Comput. Biol. 8, e1002404 (2012).","journal-title":"PLOS Comput. Biol."},{"key":"44083_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nsmb.2817","volume":"21","author":"J Petersen","year":"2014","unstructured":"Petersen, J. et al. T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat. Struct. Mol. Biol. 21, 480\u2013488 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"44083_CR27","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.4049\/jimmunol.180.5.3268","volume":"180","author":"D Stepniak","year":"2008","unstructured":"Stepniak, D. et al. Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2. J. Immunol. 180, 3268\u20133278 (2008).","journal-title":"J. Immunol."},{"key":"44083_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1053\/j.gastro.2011.04.048","volume":"141","author":"MF du Pr\u00e9","year":"2011","unstructured":"du Pr\u00e9, M. F. et al. Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells. Gastroenterology 141, 610\u2013620.e1-2 (2011).","journal-title":"Gastroenterology"},{"key":"44083_CR29","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","volume":"8","author":"LB Avery","year":"2016","unstructured":"Avery, L. B. et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs 8, 1064\u20131078 (2016).","journal-title":"MAbs"},{"key":"44083_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa, W. & Helton, D. L. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39, 1284\u20131297 (2019).","journal-title":"Cephalalgia"},{"key":"44083_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJMoa2000226","volume":"383","author":"JD Low","year":"2020","unstructured":"Low, J. D. et al. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N. Engl. J. Med. 383, 452\u2013459 (2020).","journal-title":"N. Engl. J. Med."},{"key":"44083_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/mi.2015.147","volume":"9","author":"S Dahal-Koirala","year":"2016","unstructured":"Dahal-Koirala, S. et al. TCR sequencing of single cells reactive to DQ2.5-glia-\u03b12 and DQ2.5-glia-\u03c92 reveals clonal expansion and epitope-specific V-gene usage. Mucosal Immunol. 9, 587\u2013596 (2016).","journal-title":"Mucosal Immunol."},{"key":"44083_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41594-019-0353-4","volume":"27","author":"J Petersen","year":"2020","unstructured":"Petersen, J. et al. T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. Nat. Struct. Mol. Biol. 27, 49\u201361 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"44083_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","volume":"28","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim, M. et al. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential. Cancer Gene Ther. 28, 581\u2013589 (2021).","journal-title":"Cancer Gene Ther."},{"key":"44083_CR35","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1172\/JCI130562","volume":"130","author":"CJ Holland","year":"2020","unstructured":"Holland, C. J. et al. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA. J. Clin. Investig. 130, 2673\u20132688 (2020).","journal-title":"J. Clin. Investig."},{"key":"44083_CR36","doi-asserted-by":"publisher","first-page":"9301","DOI":"10.3390\/ijms21239301","volume":"21","author":"L Falcigno","year":"2020","unstructured":"Falcigno, L. et al. Structural perspective of gliadin peptides active in celiac disease. Int. J. Mol. Sci. 21, 9301 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"44083_CR37","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1126\/science.1074129","volume":"297","author":"L Shan","year":"2002","unstructured":"Shan, L. et al. Structural basis for gluten intolerance in celiac sprue. Science 297, 2275\u20132279 (2002).","journal-title":"Science"},{"key":"44083_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1084\/jem.20012028","volume":"195","author":"LW Vader","year":"2002","unstructured":"Vader, L. W. et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J. Exp. Med. 195, 643\u2013649 (2002).","journal-title":"J. Exp. Med."},{"key":"44083_CR39","doi-asserted-by":"publisher","first-page":"e15637","DOI":"10.1371\/journal.pone.0015637","volume":"5","author":"C Mitea","year":"2010","unstructured":"Mitea, C. et al. A universal approach to eliminate antigenic properties of alpha-gliadin peptides in celiac disease. PLoS One 5, e15637 (2010).","journal-title":"PLoS One"},{"key":"44083_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2012.07.013","volume":"37","author":"SE Broughton","year":"2012","unstructured":"Broughton, S. E. et al. Biased T cell receptor usage directed against human leukocyte antigen DQ8-Restricted gliadin peptides is associated with celiac disease. Immunity 37, 611\u2013621 (2012).","journal-title":"Immunity"},{"key":"44083_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1021\/cb800314v","volume":"4","author":"S Koide","year":"2009","unstructured":"Koide, S. & Sidhu, S. S. The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins. ACS Chem. Biol. 4, 325\u2013334 (2009).","journal-title":"ACS Chem. Biol."},{"key":"44083_CR42","doi-asserted-by":"publisher","first-page":"e2116147118","DOI":"10.1073\/pnas.2116147118","volume":"118","author":"N Pishesha","year":"2021","unstructured":"Pishesha, N. et al. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. Proc. Natl. Acad. Sci. USA 118, e2116147118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"44083_CR43","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, e3000410 (2020).","journal-title":"PLoS Biol."},{"key":"44083_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1107\/S1744309107051408","volume":"63","author":"KN Henderson","year":"2007","unstructured":"Henderson, K. N. et al. The production and crystallization of the human leukocyte antigen class II molecules HLA-DQ2 and HLA-DQ8 complexed with deamidated gliadin peptides implicated in coeliac disease. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 63, 1021\u20131025 (2007).","journal-title":"Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun."},{"key":"44083_CR45","doi-asserted-by":"publisher","first-page":"11828","DOI":"10.1073\/pnas.95.20.11828","volume":"95","author":"L Gauthier","year":"1998","unstructured":"Gauthier, L. et al. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc. Natl. Acad. Sci. USA 95, 11828\u201311833 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"44083_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-8-41","volume":"8","author":"A Predonzani","year":"2008","unstructured":"Predonzani, A., Arnoldi, F., L\u00f3pez-Requena, A. & Burrone, O. R. In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol. 8, 41 (2008).","journal-title":"BMC Biotechnol."},{"key":"44083_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81669-8","volume":"11","author":"H Muramatsu","year":"2021","unstructured":"Muramatsu, H. et al. Novel myostatin-specific antibody enhances muscle strength in muscle disease models. Sci. Rep. 11, 2160 (2021).","journal-title":"Sci. Rep."},{"key":"44083_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/19420862.2015.1110660","volume":"8","author":"N Hironiwa","year":"2016","unstructured":"Hironiwa, N. et al. Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation. MAbs 8, 65\u201373 (2016).","journal-title":"MAbs"},{"key":"44083_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","volume":"131","author":"M Legut","year":"2018","unstructured":"Legut, M., Dolton, G., Mian, A. A., Ottmann, O. G. & Sewell, A. K. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood 131, 311\u2013322 (2018).","journal-title":"Blood"},{"key":"44083_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D. Biol. Crystallogr. 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"44083_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"44083_CR52","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D. Biol. Crystallogr. 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"44083_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D. Biol. Crystallogr. 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"44083_CR54","unstructured":"Tickle, I. J. et al. STARANISO version 2.3.63 (20210223). (Global Phasing Ltd., Cambridge, United Kingdom, 2018)."},{"key":"44083_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"44083_CR56","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1073\/pnas.0306885101","volume":"101","author":"CY Kim","year":"2004","unstructured":"Kim, C. Y., Quarsten, H., Bergseng, E., Khosla, C. & Sollid, L. M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc. Natl. Acad. Sci. USA. 101, 4175\u20134179 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"44083_CR57","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"44083_CR58","unstructured":"Bricogne, G. et al. \u201cBUSTER version 2.11.8\u201d (Global Phasing Ltd., Cambridge, United Kingdom, 2017)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44083-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44083-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:03:42Z","timestamp":1703243022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44083-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44083"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-44083-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.Okura., Y.I.-T., A.M. are employees of Chugai Pharmaceutical and inventors on patents (WO 2022\/059766) related to the antibodies to HLA-DQ, of which all rights have been assigned to the company. Y.Okura., N.T., T.Tsushima., Z.H. are employees of Chugai Pharmaceutical and inventors on patents (WO 2019\/069993) related to the antibodies to HLA-DQ, of which all rights have been assigned to the company. Y.Okura., N.T. are employees of Chugai Pharmaceutical and inventors on patents (WO 2018\/155692) related to the antibodies to HLA-DQ, of which all rights have been assigned to the company. L.M. Sollid., either privately or via his employer, has been a consultant during the last 3 years for Amagma Therapeutics, Bristol Myers Squibb, Chugai Pharmaceutical, Glaxo Smith Klein, Intrexon Actobiotics, Mozart Therapeutics, Ono Pharmaceutical, SQZ Biotech, and Topas Therapeutics and he is inventor on a patent application describing gluten pHLA-DQ2.5-specific antibodies (WO 2019\/158602). The other authors are employees of Chugai Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd. is involved in the research and development of medicines. This study was funded by Chugai Pharmaceutical Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8502"}}